- Home
- REX vs PLRX Comparison
REX vs PLRX Comparison
Compare REX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- PLRX
- Stock Information
- Founded
- REX 1980
- PLRX 2015
- Country
- REX United States
- PLRX United States
- Employees
- REX N/A
- PLRX N/A
- Industry
- REX Major Chemicals
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- REX Industrials
- PLRX Health Care
- Exchange
- REX Nasdaq
- PLRX Nasdaq
- Market Cap
- REX 800.0M
- PLRX 641.5M
- IPO Year
- REX N/A
- PLRX 2020
- Fundamental
- Price
- REX $40.12
- PLRX $13.21
- Analyst Decision
- REX Strong Buy
- PLRX Strong Buy
- Analyst Count
- REX 1
- PLRX 7
- Target Price
- REX $55.00
- PLRX $40.50
- AVG Volume (30 Days)
- REX 229.4K
- PLRX 591.6K
- Earning Date
- REX 12-03-2024
- PLRX 11-07-2024
- Dividend Yield
- REX N/A
- PLRX N/A
- EPS Growth
- REX 37.28
- PLRX N/A
- EPS
- REX 3.82
- PLRX N/A
- Revenue
- REX $671,877,000.00
- PLRX N/A
- Revenue This Year
- REX N/A
- PLRX N/A
- Revenue Next Year
- REX $9.87
- PLRX N/A
- P/E Ratio
- REX $10.50
- PLRX N/A
- Revenue Growth
- REX N/A
- PLRX N/A
- 52 Week Low
- REX $39.02
- PLRX $10.22
- 52 Week High
- REX $60.79
- PLRX $19.62
- Technical
- Relative Strength Index (RSI)
- REX 35.12
- PLRX 43.89
- Support Level
- REX $40.23
- PLRX $13.14
- Resistance Level
- REX $42.00
- PLRX $15.00
- Average True Range (ATR)
- REX 1.83
- PLRX 0.81
- MACD
- REX -0.06
- PLRX -0.12
- Stochastic Oscillator
- REX 10.31
- PLRX 5.13
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.